

Effective 1 October 2010

**Urine
Instrumented Initial Test Facility
(IITF)
Application Form**

***National Laboratory Certification Program
(NLCP)***

***RTI International
Center for Forensic Sciences
3040 Cornwallis Road
P.O. Box 12194
Research Triangle Park, North Carolina 27709***

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930-0158. Public reporting burden for this collection of information is estimated to average 4 hours per respondent per year, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 1 Choke Cherry Road, Room 7-1044, Rockville, Maryland, 20857.

**NATIONAL LABORATORY CERTIFICATION PROGRAM
URINE IITF APPLICATION FORM**

A. Applicant IITF

1. Name of IITF: _____
Address: _____

City, State, ZIP: _____
Telephone: (____) ____ - _____ FAX: (____) ____ - _____
e-Mail: _____

2. Express delivery address (*if different from above*)
Address: _____

City, State, ZIP: _____

3. Designated Responsible Technician (RT): _____
Title/Position: _____
Telephone: (____) ____ - _____ Ext. _____
e-Mail: _____

If applicable:

Designated Alternate RT (Alt-RT): _____
Title/Position: _____
Telephone: (____) ____ - _____ Ext. _____
e-Mail: _____

4. **I understand that the answers provided in this application will be used to determine the applicant IITF's potential eligibility for the National Laboratory Certification Program. To the best of my knowledge and belief, the answers recorded herein are true and complete as of this date.**

Signature, Designated RT Date

NOTE: Any false, fictitious, or fraudulent statements or information presented in this application form could subject you to prosecution, monetary penalties, or both. See Sec. 18 U.S.C. 1001; 31 U.S.C. 3801-812.

B. General IITF Information

The following table is excerpted from Section 3.4 of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Federal Register, 73 FR 71858, 25 November 2008, effective 1 October 2010). **Note:** confirmatory test information is not applicable for IITFs.

Initial Test Analyte	Initial Test Cutoff Concentration	Confirmatory Test Analyte	Confirmatory Test Cutoff Concentration
Marijuana metabolites	50 ng/mL	THCA ¹	15 ng/mL
Cocaine metabolites	150 ng/mL	Benzoyllecgonine	100 ng/mL
Opiate metabolites			
Codeine/Morphine ²	2000 ng/mL	Codeine	2000 ng/mL
		Morphine	2000 ng/mL
6-Acetylmorphine	10 ng/mL	6-Acetylmorphine	10 ng/mL
Phencyclidine	25 ng/mL	Phencyclidine	25 ng/mL
Amphetamines ³			
AMP/MAMP ⁴	500 ng/mL	Amphetamine	250 ng/mL
		Methamphetamine ⁵	250 ng/mL
MDMA ⁶	500 ng/mL	MDMA	250 ng/mL
		MDA ⁷	250 ng/mL
		MDEA ⁸	250 ng/mL
¹ Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA).			
² Morphine is the target analyte for codeine/morphine testing.			
³ Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.			
⁴ Methamphetamine is the target analyte for amphetamine/methamphetamine testing			
⁵ To be reported positive for methamphetamine, a specimen must also contain amphetamine at a concentration equal to or greater than 100 ng/mL.			
⁶ Methylenedioxymethamphetamine (MDMA).			
⁷ Methylenedioxyamphetamine (MDA).			
⁸ Methylenedioxyethylamphetamine (MDEA).			

1. To be eligible for certification, the IITF must test for all initial drug test analytes and initial specimen validity test measurands required by the Mandatory Guidelines for Federal Workplace Drug Testing Programs (*Federal Register*, 73 FR 71858, 25 November 2008, effective 1 October 2010). The IITF must use the test methods specified by the Mandatory Guidelines for screening and initial tests (i.e., drug tests and specimen validity tests). **Note:** the terms “screening specimen validity test” and “initial specimen validity test” are defined in Section J of the NLCP Manual for Urine IITFs.

1a. Does the IITF have validated initial drug test assays for the drug classes required by the Mandatory Guidelines?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

1b. Does the IITF use an immunoassay method approved, cleared, or otherwise recognized as accurate and reliable by the U.S. Food and Drug Administration (FDA) for the initial drug tests?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

1c. Does the IITF have validated tests to assess specimen validity as required by the Mandatory Guidelines (i.e., at a minimum, tests for creatinine, pH, specific gravity, and one or more oxidizing adulterants)?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

2. Is the IITF registered with the U.S. Drug Enforcement Agency (DEA)?

Yes → **ATTACH PHOTOCOPY OF REGISTRATION CERTIFICATE**
 No → **COMMENT BELOW**

If YES, which schedules are covered by the registration?

1 2 2N 3 3N 4 5

If NO, explain how controlled reference materials are acquired: _____

3. Describe the State licensure requirements for urine forensic toxicology for the State in which the IITF is located. _____

4. List IITF certifications/licenses:

States (List): _____

CLIA/HCFA¹ (List Specialties): _____

CAP² (List Specialties): _____

Others (Specify): _____

¹Clinical Laboratory Improvement Amendments (CLIA)/Health Care Financing Administration (HCFA)

²College of American Pathologists (CAP)

4a. **ATTACH PHOTOCOPIES OF ALL LICENSES AND CERTIFICATIONS INDICATED ABOVE.**

5. To be eligible for certification, the IITF must obtain a letter of commitment from one or more HHS-certified laboratories stating that the laboratory will receive, test, and report specimens from the certified IITF. The letter must be signed by each Responsible Person (RP) of the laboratory and by the designated RT of the applicant IITF. The list of currently certified laboratories is published by SAMHSA monthly in the Federal Register and is available on the SAMHSA website, <http://workplace.samhsa.gov/>.

5a. Does the IITF have a letter of commitment from one or more HHS-certified laboratories?

- Yes → **ATTACH PHOTOCOPIES OF ALL LABORATORY
COMMITMENT LETTERS**
- No → **IITF NOT ELIGIBLE TO APPLY**

C. IITF Standard Operating Procedures (SOP) Manual

1. For certification, the IITF must have a complete SOP manual that will apply to testing of regulated specimens under the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Federal Register, 73 FR 71858, 25 November 2008, effective 1 October 2010).

Note: Manufacturers' package inserts or instrument manuals are not considered formal procedures. A written SOP manual is required to be eligible to apply for certification and it must be completed before the IITF is eligible to receive NLCP performance testing (PT) samples.

1a. Does the IITF have a complete SOP manual for regulated drug testing?

- Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

IITF SOP MANUAL INDEX

Indicate the location for each of these topics in the IITF's SOP manual:

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Security		
Procedure for controlling access to the drug testing facility	_____	_____
Procedure for controlling access to individual secured areas	_____	_____
Procedure for documenting visitor access	_____	_____
Accessioning (Specimen receipt)		
Procedure for receipt and processing of specimens	_____	_____
Procedure for problem/rejected specimens	_____	_____
Chain-of-Custody		
Procedure for documenting all transfers of specimens	_____	_____
Procedure for documenting all transfers of aliquots	_____	_____
Procedure for maintaining security of specimen bottles	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Procedure for maintaining security of specimen aliquots	_____	_____
Procedure for sending a specimen to a laboratory	_____	_____
<i>Aliquot Preparation</i>		
Procedure for preparing initial drug test aliquots	_____	_____
Procedure for preparing screening specimen validity test aliquots	_____	_____
Procedure for preparing initial specimen validity test aliquots	_____	_____
Procedures for automated aliquotting equipment	_____	_____
<i>Initial Drug Test</i>		
Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedure for calculating results	_____	_____
Quality control (QC) procedure and criteria for acceptable results and corrective actions	_____	_____
Procedure for validation of initial drug test methods	_____	_____
References	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Second Initial Drug Test		
Criteria for use	_____	_____
Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedure for calculating results	_____	_____
QC procedure and criteria for acceptable results and corrective actions	_____	_____
Procedure for validation of second initial drug test methods	_____	_____
References	_____	_____

Specimen Validity Tests

Note: Provide the following information for each specimen validity test (Screening and Initial tests are defined in Section J of the NLCP Manual for Urine IITFs)

Creatinine

Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedures for conducting creatinine tests	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
QC acceptance/rejection criteria and corrective action for creatinine tests	_____	_____
Procedure for validation of creatinine test methods	_____	_____
Procedure for periodic re-verification of creatinine test methods	_____	_____
Special requirements, etc.	_____	_____
References	_____	_____
Specific Gravity		
Principle of analysis	_____	_____
Preparation of calibrators and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedures for conducting specific gravity tests	_____	_____
QC acceptance/rejection criteria and corrective action for specific gravity tests	_____	_____
Procedure for validation of specific gravity test method	_____	_____
Special requirements, etc.	_____	_____
References	_____	_____
Criteria for identifying acceptable, dilute, and possible invalid or substituted specimens based on creatinine and specific gravity test results	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
pH		
Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedures for conducting pH tests	_____	_____
QC acceptance/rejection criteria and corrective action for pH tests	_____	_____
Criteria for identifying acceptable and possible invalid or adulterated specimens based on pH test results	_____	_____
Procedure for validation of pH test methods	_____	_____
Special requirements, etc.	_____	_____
References	_____	_____
Oxidants		
Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedures for conducting oxidant tests	_____	_____
QC acceptance/rejection criteria and corrective action for oxidant tests	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Criteria for identifying acceptable and possible invalid or adulterated specimens based on oxidant test results	_____	_____
Procedure for validation of oxidant test methods	_____	_____
Procedure for periodic re-verification of oxidant test methods	_____	_____
Special requirements, etc.	_____	_____
References	_____	_____

Other Adulterants

Note: Provide the following information for each adulterant

Adulterant: _____

Principle of analysis	_____	_____
Preparation of reagents, calibrators, and controls	_____	_____
Procedure for set-up and normal operation of instruments	_____	_____
Procedure for instrument maintenance	_____	_____
Procedure for assay calibration	_____	_____
Procedures for conducting the test	_____	_____
QC acceptance/rejection criteria and corrective action for the test	_____	_____
Criteria for identifying acceptable and possible invalid or adulterated specimens based on the adulterant test results	_____	_____
Procedure for validation of the test methods	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Procedure for periodic re-verification of the test methods	_____	_____
Special requirements, etc.	_____	_____
References	_____	_____
QC Materials and Reagents		
Procedures for preparing stock standards, etc.	_____	_____
Procedures for preparing and verifying calibrators	_____	_____
Procedures for preparing and verifying controls	_____	_____
Corrective procedure when QC verification results are out of control limits	_____	_____
Procedures for preparing and verifying reagents	_____	_____
Corrective procedure when reagent verification results are unacceptable	_____	_____
Quality Assurance (QA) Procedures		
Procedures for monitoring control results	_____	_____
Corrective procedure when QA review of control results shows problems or potential problems (e.g., trends, shifts, bias)	_____	_____
Equipment and Maintenance		
Wash procedure for labware	_____	_____
Procedure for determining accuracy and precision of pipetting devices	_____	_____
Procedures for temperature-dependent equipment	_____	_____
Procedures for centrifuges	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Procedures for analytical balances	_____	_____
Safety procedures	_____	_____
<i>Administrative/Reporting Procedures</i>		
Procedure for reviewing/certifying the test result(s) of a specimen	_____	_____
Procedure for reporting the test result(s) of a specimen	_____	_____
Procedure to detect and correct clerical errors	_____	_____
Procedure for electronic reporting of results	_____	_____
Procedure for preparing statistical summary reports	_____	_____
Procedure for updating the SOP Manual	_____	_____
Procedure for preparing data packages	_____	_____
Procedure for preparing the Forwarded and Rejected Specimen List (FRSL)	_____	_____
<i>IITF Computer System Procedures</i>		
Computer and Laboratory Information Management System (LIMS) security procedures	_____	_____
Computer and LIMS maintenance procedures	_____	_____
Procedure for computer and software validation	_____	_____
Procedure for requesting, verifying, and implementing software and configuration changes	_____	_____
Procedure for LIMS records archiving and retrieval	_____	_____

<u>TOPIC</u>	<u>SECTION</u>	<u>PAGE NO.</u>
Procedures for system monitoring, incident response, and disaster recovery	_____	_____
Procedure for obtaining audit trail reports	_____	_____

D. Chain of Custody, Accessioning, and Security

The IITF must have chain of custody, accessioning, and security procedures that ensure integrity is maintained for the original specimens and their aliquots. The chain of custody forms and procedures must account for all individuals who handle the specimens and aliquots. The chain of custody forms and procedures should provide a clear picture of the handling/transfers of specimens and aliquots from initial receipt to final disposition. The IITF must ensure the security of specimens and aliquots during processing and placement in any storage locations.

1. Provide a description of the IITF's chain of custody procedures for the following:

Specimen Receiving/Accessioning

- Receipt of specimen packages, how they are handled, who reviews the accuracy of the information on the custody and control forms and how discrepancies are documented
- Assignment of IITF accession numbers
- Handling and resolution of problems with specimen bottles and/or custody and control forms
- Location of temporary storage area(s)

Aliquotting Procedures

- Aliquotting from the original specimen bottles (i.e., who and where)
- The aliquotting procedure (pouring or pipetting and amounts) used for preparing aliquots for initial drug tests, screening specimen validity tests, and initial specimen validity tests
- Transfer of aliquots from the individuals performing the aliquotting to those who will be testing the aliquots

Initial Drug Tests (First and Second Tests)

- Handling and testing of aliquots by IITF personnel
- Maintenance of chain of custody and aliquot identity during the testing

Specimen Validity Tests (Screening, Initial)

- Handling and testing of aliquots by IITF personnel
 - Maintenance of chain of custody and aliquot identity during the testing
- Note:** the terms "screening specimen validity test" and "initial specimen validity test" are defined in Section J of the NLCP Manual for Urine IITFs.

Disposition of Specimens and Aliquots

- Handling of original specimen bottles and aliquots after testing is completed
- Procedure for transferring specimens to an HHS-certified laboratory

Note: (1) Insert here.

(2) Do not exceed a total of 3 pages.

2. Attach a flowchart and/or examples of chain of custody documents showing how regulated specimens and aliquots will be processed and their custody documented (chain of custody documents may be referenced and/or provided as examples for clarification).
3. Will regulated specimens be accessioned in a limited access, secure area?
 - Yes
 - No → **IITF NOT ELIGIBLE TO APPLY**
4. Will regulated specimens be tested in a limited access, secure area?
 - Yes
 - No → **IITF NOT ELIGIBLE TO APPLY**
5. Attach a floorplan of the IITF indicating the areas to be used for accessioning, testing of specimens, and storage of specimens, aliquots, and records. Include information to describe how the areas are secured and what security devices are utilized (e.g., which walls are outside walls; which are secured up to the ceiling; the location and type of security devices such as magnetic key cards, cipher locks, padlocks; location of secured storage areas such as refrigerators or freezers and how they are secured).
6. Will the original specimens be maintained in a limited access, secured area at all times?
 - Yes
 - No → **IITF NOT ELIGIBLE TO APPLY**

6a. Where will the original specimens be stored?

Before testing? _____

During testing? _____

After testing is complete? _____

6b. Who will have access to the specimen storage areas?

Before testing? _____

During testing? _____

After testing is complete? _____

E. Records

The IITF must maintain records to support test results (i.e., including but not limited to all associated QC results, analytical data, chain of custody documents and associated administrative records) for at least two years. The IITF must also maintain method validation records for past and current procedures, instrument validation records, records documenting the standard operating procedures used at any given time period, and records of the education, training, and certification of all employees associated with regulated testing. The IITF must have security measures in place to limit access to electronic and hardcopy records to essential authorized personnel.

1. Will the IITF maintain records supporting specimen test results for at least two years?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

- 1a. Will there be a secured area for the storage of records supporting specimen test results?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

2. Will the IITF limit records access to authorized personnel?

Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

3. Attach two data packages using the format described in Section R of the NLCP Manual for Urine Instrumented Initial Test Facilities to support (1) a negative drug test result and (2) a possible adulterated, substituted, or invalid result based on specimen validity testing.

___ Yes → **Describe:** _____

___ No → **CANDIDATE NOT ELIGIBLE AS RT**

4. In the table below, enter the candidate's education.

Education	Name of School	Major and Minor Fields of Study	Diploma, Certificate or Degree Received
College or University			
Other Schools Attended			

5. Is the candidate a full-time or part-time employee of the IITF?

___ Full-time (at least 40 hours per week)
 ___ Part-time _____ hours per week

If not a full- or part-time employee, what is the relationship between the candidate and the IITF?

6. How many hours per week will the candidate work in the forensic urine drug testing IITF?

_____ HOURS PER WEEK

7. How long has the candidate been associated with the IITF?

_____ YEARS

4. In the table below, enter the candidate's education.

Education	Name of School	Major and Minor Fields of Study	Diploma, Certificate or Degree Received
College or University			
Other Schools Attended			

5. Is the candidate a full-time or part-time employee of the IITF?

- ___ Full-time (at least 40 hours per week)
- ___ Part-time _____ hours per week

If not a full- or part-time employee, what is the relationship between the candidate and the IITF?

6. How many hours per week will the candidate work in the forensic urine drug testing IITF?

_____ HOURS PER WEEK

7. How long has the candidate been associated with the IITF?

_____ YEARS

Personnel Certifications and Licenses

1. List the name, job title, education, and licenses/certifications for the following key staff:

Note: (1) Attach a résumé for each individual listed below.

(2) Attach a separate sheet as needed to list all individuals in these positions.

	Name	Job Title	Education	License/ Certification
Certifying Technician(s)				
Supervisor(s)				
Other Key Staff				

2. Is licensure and/or certification required for any of the above positions in the State in which the IITF is located?

- Yes
- No → **GO TO SECTION G**

If YES, describe requirements:

G. Quality Control

For certification, the IITF must have clearly defined QC procedures that are consistently applied, subject to review, and prompt appropriate corrective action upon failure to meet established acceptance criteria.

1. Are instrument function checks reviewed prior to batch analysis?

- Yes → **COMPLETE 1a**
 No

1a. What is the title and/or position of the person responsible for these checks?

Title/Position: _____

2. Are corrective actions documented when controls, instrument responses, etc., fail defined acceptance criteria?

- Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

3. Are all QC results reviewed by the Certifying Technician prior to the release of the results?

- Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

4. Is the QA/QC program under the direct supervision of a Quality Control Supervisor?

- Yes
 No → **COMPLETE 4a**

4a. What is the title/position of the person responsible for the QA/QC program?

Title/Position: _____

5. Is the QA/QC program reviewed periodically by the Responsible Technician Candidate?

- Yes
 No → **CANDIDATE NOT ELIGIBLE AS RT**

5a. What is the title/position of the person responsible for the periodic review?

Title/Position: _____

6. Are there written procedures that are employed to routinely detect clerical and analytical errors prior to reporting results?

- Yes
 No → **IITF NOT ELIGIBLE TO APPLY**

7. For certification, the IITF must have a QC program that includes both blind and open QC samples. At a minimum, these must include the number and type of QC samples described in the Mandatory Guidelines for drug and specimen validity tests.

Provide a description of the IITF's procedures for the following:

Specimen Accessioning

- Introduction and /or aliquotting of blind samples into the test batches by accessioners
- Content and concentration of each blind sample
- If applicable, preparation and submission of blind samples as donor specimens from external sources

Initial Drug Tests (First and Second)

- How batches are constituted (e.g., how many specimens are in a batch, is it constituted in one session or are specimens added to the batch throughout the day?)
- The distribution of the donor specimens and QC samples within each batch
- The procedure(s) and acceptance criteria for calibration and when and by whom the calibration data are evaluated and documented
- The acceptance criteria for each control (open and blind) in each batch and when and by whom these are evaluated and documented
- The criteria for accepting all donor specimen results or only a partial number of donor specimens in a batch

Specimen Validity Tests (Screening, Initial)

- How batches are constituted (e.g., how many specimens are in a batch, is it constituted in one session or are specimens added to the batch throughout the day?)
- The distribution of the donor specimens and QC samples within each batch
- The procedure(s) and acceptance criteria for calibration and when and by whom the calibration data are evaluated and documented
- The acceptance criteria for each control (open and blind) in each batch and when and by whom these are evaluated and documented
- The criteria for accepting all donor specimen results or only a partial number of donor specimens in a batch
- Include an outline or a legible flow chart that comprehensively describes the IITF's specimen validity testing. The IITF's submission must identify any "reflex" testing, the initial test methods for each specimen validity test measurand, and any screening tests.

Note: (1) Insert here.

(2) Do not exceed a total of 2 pages.

H. Review and Reporting

The IITF must have adequate procedures to ensure the thorough review and accurate reporting of results.

1. Briefly describe the procedures for reviewing initial drug test data and certifying negative results (i.e., title/position of reviewers, electronic/hardcopy documents reviewed, QC review): _____

2. Briefly describe the procedures for reviewing specimen validity test data/results (i.e., screening and initial tests): _____

3. Briefly describe the procedures for the reporting of results. If the IITF will use electronic reporting for any regulated specimens, describe procedures to ensure confidentiality: _____

4. Is the IITF's custody and control form (CCF) identical to the OMB-approved Federal CCF to be used for all specimens submitted for testing under the Mandatory Guidelines?

___ Yes → **ATTACH EXAMPLE OF IITF'S CUSTODY AND CONTROL FORM**
___ No → **IITF NOT ELIGIBLE TO APPLY**

5. Will the IITF use computer-generated electronic reports for specimens submitted for testing under the Mandatory Guidelines?

___ Yes → **ATTACH EXAMPLE REPORTS (SEE BELOW)**
___ No

If YES, attach an example of the IITF's computer-generated electronic report for each of the following IITF results:

- Negative
- Negative, Dilute
- Rejected

I. IITF Computer Systems

IITF computer systems include any computer system used in processing regulated specimens. Such systems are typically used for accessioning specimens, batch assignment and scheduling, capturing test results, tabulating QC data, and reporting final results. HHS-certified laboratories are prohibited from transmitting data to an IITF through a computer interface. Any computer interface communicating any form of data from an HHS-certified IITF to a laboratory must be approved by the NLCP prior to implementation. The applicant IITF and/or laboratories must submit a detailed plan to the NLCP for review.

1. Give a brief description of the computer system to be utilized by the IITF. Is it a “stand alone” system used solely by the IITF, part of a local system (e.g., a hospital system), or part of a multi-facility corporate system? (If not on-site, provide information on its location and organizational control of the system.)

2. Give a brief description of how the IITF plans to use the computer system in regulated specimen processing: _____

3. Is the IITF computer system maintained in a secure area?

____ Yes

____ No

Attach a floorplan identifying the IITF computer system location. Include information to describe how the area is secured and what security devices are utilized (e.g., which walls are outside walls; which are secured up to the ceiling; the location and type of security devices such as magnetic key cards, cipher locks, padlocks).

4. Does the IITF limit functional access to the computer system?

____ Yes

____ No

Complete the NLCP Application Tables

Table 1-a.	First and Second Initial Drug Test Methods and Instruments
Table 1-b.	First Initial Drug Test QC samples
Table 1-c.	Second Initial Drug Test QC samples
Table 2-a-1.	Initial Specimen Validity Test Methods and Instruments (continued on Table 2-a-2 as needed)
Table 2-b-1.	<i>not applicable for an IITF</i>
Table 2-c-1.	Screening Specimen Validity Test Methods and Instruments (continued on Table 2-c-2 as needed)
Table 2-d-1.	Initial Specimen Validity Test QC samples (continued on Table 2-d-2 as needed)
Tables 2-d-3 and 2-d-4.	<i>not applicable for an IITF</i>
Table 2-d-5.	Screening Specimen Validity Test QC samples

Table 1-a

Initial Drug Test Methods and Instruments

IITF

First Initial Drug Test Methods and Instruments							
First Initial Drug Test	THCA (marijuana metabolites)	BZE (cocaine metabolites)	MOR (opiate metabolites)	6-AM	PCP	MAMP (amphetamines)	MDMA
Kit and Manufacturer							
Analyzer and Manufacturer							
Number of Analyzer Units							
Calibration Method							
Maximum Batch Size							
*If "Other" is selected, please specify:							
Second Initial Drug Test Methods and Instruments							
Second Initial Drug Test	THCA (marijuana metabolites)	BZE (cocaine metabolites)	MOR (opiate metabolites)	6-AM	PCP	MAMP (amphetamines)	MDMA
Kit and Manufacturer							
Analyzer and Manufacturer							
Number of Analyzer Units							
Calibration Method							
Maximum Batch Size							
*If "Other" is selected, please specify:							

THCA = Δ9-tetrahydrocannabinol-9-carboxylic acid

MOR = morphine

6-AM = 6-acetylmorphine

MDMA = methylenedioxyamphetamine

BZE = benzoylecgonine

PCP = phencyclidine

MAMP = methamphetamine

Table 1-b

First Initial Drug Test QC Samples

IITF

1st initial drug test QC		Cal 1	Cal 2	Cal 3	Cal 4	Control 1	Control 2	Control 3	Control 4	BQC 1	BQC 2
THCA	Conc										
	Matrix										
	Source										
BZE	Conc										
	Matrix										
	Source										
MOR	Conc										
	Matrix										
	Source										
6-AM	Conc										
	Matrix										
	Source										
PCP	Conc										
	Matrix										
	Source										
MAMP	Conc										
	Matrix										
	Source										
MDMA	Conc										
	Matrix										
	Source										
*If "Other" is selected, please specify:											

BQC = blind quality control sample

2nd initial drug test QC		Cal 1	Cal 2	Cal 3	Cal 4	Control 1	Control 2	Control 3	Control 4	BQC 1	BQC 2
THCA	Conc										
	Matrix										
	Source										
BZE	Conc										
	Matrix										
	Source										
MOR	Conc										
	Matrix										
	Source										
6-AM	Conc										
	Matrix										
	Source										
PCP	Conc										
	Matrix										
	Source										
MAMP	Conc										
	Matrix										
	Source										
MDMA	Conc										
	Matrix										
	Source										
*If "Other" is selected, please specify:											

Table 2-a-1

Initial Specimen Validity Test Methods and Instruments

IITF

Initial SVT	Creatinine	pH Meter*	Nitrite	Gen.Oxid.	Other:	Other:
Method						
Kit Manufacturer						
Analyzer and Manufacturer						
Number of Analyzer Units						
Unit of Measurement	mg/dL		mcg/mL			
Target Analyte of Assay						
Target Analyte of Calibrator						
Calibration Method						
LOD						
LOQ						
ULOL						
Carryover Limit						
Maximum Batch Size						
*If "Other" is selected, please specify:						

SG = specific gravity

Gen. Oxid. = general oxidant

LOD = limit of detection

LOQ = limit of quantitation

ULOL= upper limit of linearity

*also applies to a colorimetric pH test with dynamic range of at least 2.0 to 12.0

Table 2-a-2

Initial Specimen Validity Test Methods and Instruments

IITF

Initial SVT cont.	Other:	Other:	Other:	Other:	Other:	Other:	Other:
Method							
Kit Manufacturer							
Analyzer and Manufacturer							
Number of Analyzer Units							
Unit of Measurement							
Target Analyte of Assay							
Target Analyte of Calibrator							
Calibration Method							
LOD							
LOQ							
ULOL							
Carryover Limit							
Maximum Batch Size							
*If "Other" is selected, please specify:							

Table 2-c-1

Screening Specimen Validity Test Methods and Instruments

IITF

Screening SVT	SG	pH	Other:	Other:	Other:
Method					
Kit Manufacturer					
Analyzer and Manufacturer					
Number of Analyzer Units					
Unit of Measurement					
Target Analyte of Assay					
Target Analyte of Calibrator					
Calibration Method					
LOD					
LOQ					
ULOL					
Carryover Limit					
Maximum Batch Size					
*If "Other" is selected, please specify:					

Table 2-c-2

Screening Specimen Validity Test Methods and Instruments

IITF

Screening SVT cont.	Other:	Other:	Other:	Other:	Other:
Method					
Kit Manufacturer					
Analyzer and Manufacturer					
Number of Analyzer Units					
Unit of Measurement					
Target Analyte of Assay					
Target Analyte of Calibrator					
Calibration Method					
LOD					
LOQ					
ULOL					
Carryover Limit					
Maximum Batch Size					
*If "Other" is selected, please specify:					

Table 2-d-1

Initial Specimen Validity Test
QC Samples

IITF

Initial SVT QC		Cal 1	Cal 2	Cal 3	Cal 4	Cal 5	Control 1	Control 2	Control 3	Control 4	Control 5
Creatinine	Target value										
	Matrix										
	Source										
pH Meter*	Target value										
	Matrix										
	Source										
Nitrite	Target value										
	Matrix										
	Source										
Gen Oxid	Target value										
	Matrix										
	Source										
*If "Other" is selected, please specify:											

*also applies to a colorimetric pH test with dynamic range of at least 2.0 to 12.0

Table 2-d-2

Initial Specimen Validity Test
QC Samples

IITF

Initial SVT QC cont.		Cal 1	Cal 2	Cal 3	Cal 4	Cal 5	Control 1	Control 2	Control 3	Control 4	Control 5
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
*If "Other" is selected, please specify:											

Table 2-d-5

Screening
Specimen Validity Test
QC Samples

IITF

Screening SVT QC		Cal 1	Cal 2	Cal 3	Cal 4	Cal 5	Control 1	Control 2	Control 3	Control 4	Control 5
Specific Gravity	Target Value										
	Matrix										
	Source										
pH	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
Other (enter name):	Target Value										
	Matrix										
	Source										
*If "Other" is selected, please specify:											